Hotbed/Location

Found 582,237 articles

• First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout

  9/23/2020

  Swedish Orphan Biovitrum AB and Selecta Biosciences, Inc. announced the commencement of the phase 3 clinical programme of SEL-212 for chronic refractory gout, with the randomisation of the first patient in the study.

• Medtronic Evaluates Insertable Cardiac Monitor in Identifying Patients at High Risk of Worsening Heart Failure

  9/23/2020

  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first enrollments in the ALLEVIATE-HF clinical trial which will evaluate the ability of its Reveal LINQ™ Insertable Cardiac Monitor (ICM) in identifying patients at high-risk of worsening heart failure

• Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell TherapyAthenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S.

  9/23/2020

  Athenex, Inc. announced that the U.S. Food and Drug Administration has allowed its Investigational New Drug application for TCRT-ESO-A2, an autologous T cell receptor -T cell therapy targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients.

• Lexaria Receives Orders for 4.4 Million Servings of DehydraTECH-Enabled CBD Powders

  9/23/2020

  Lexaria Bioscience Corp. is pleased to announce that it is in receipt of purchase-order commitments for approximately 4.4 million CBD servings of its patented DehydraTECHTM enabled CBD powders,

• Allevion Therapeutics Closes Additional Funding and Announces New Board Member, Jack Wang, Ph.D.

  9/23/2020

  Jack Wang, Ph.D., is the newest member to join to Allevion Therapeutics' board of directors.

• First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout

  9/23/2020

  Swedish Orphan Biovitrum AB and Selecta Biosciences, Inc. announced the commencement of the phase 3 clinical program of SEL-212 for chronic refractory gout, with the randomization of the first patient in the study.

• MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics

  9/23/2020

  Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients

• Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies

  9/23/2020

  - Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - - In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions - MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP

• Eagle Pharmaceuticals’ Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute (“RTD”) Formulation, with Launch Expected in January 2021

  9/23/2020

  Eagle Pharmaceuticals, Inc. announced that its marketing partner, SymBio Pharmaceuticals Limited, has received regulatory approval for TREAKISYM ready-to-dilute liquid formulation from the Pharmaceuticals and Medical Devices Agency in Japan.

• Halo Signs Definitive Agreement to Acquire Cannafeels

  9/23/2020

  Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) has entered into a definitive share exchange agreement, dated effective September 22, 2020 (the “Share Exchange Agreement”), with 1265292 B.C. Ltd., doing business as Cannafeels (“Cannafeels”), and the shareholders of Cannafeels (the “Shareholders”),

• NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

  9/23/2020

  Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol

• BD Submits Pre-Market Approval Supplement to FDA to Enable ThinPrep® Pap Test™ PreservCyt® Solution to be Used with the BD Onclarity™ HPV Assay

  9/23/2020

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the use of the ThinPrep ® Pap Test™ PreservCyt ® Solution vial as an approved sample type for its B

• The Bloc's New Science Foundry Practice Merges Science With Behavorial Psychology To Transform Medical Communications

  9/23/2020

  The leading independent health creative agency, The Bloc, announced today the launch of The Bloc Science Foundry, a groundbreaking new medical communications practice area that merges deep scientific expertise with applied behavioral psychology research.

• CILcare-CBSET Nominated for the Prestigious PRIX Galien Medstartup Award in the 'Best Collaboration Dedicated to the Developing or Underserved Populations Worldwide' Category

  9/23/2020

  CBSET Inc., a not-for-profit translational research institute, announced today that the company and its partner, CILcare, a leading CRO specializing in hearing disorders, have been nominated to receive a prestigious Prix Galien Medstartup award for their collaboration in fighting hearing loss; the collaborators are nominated in the category ‘Best Collaboration Dedicated to the Developing or Underserved Populations Worldwide.’

• TransEnterix Ushers in New Era of Robotic Surgery with First Usage of Machine Vision Capabilities

  9/23/2020

  Intelligent Surgical Unit Enables Augmented Intelligence on the Senhance System

• Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19

  9/23/2020

  Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®

• Vela Diagnostics' SARS-CoV-2 RT-PCR Test v2.0 Authorized for Emergency Use in the U.S.

  9/23/2020

  Vela Diagnostics' automated COVID-19 detection kit receives Emergency Use Authorization from the FDA.

• Novian Health Chosen as One o the Top 50 Medtech Startups Transforming the Healthcare Industry

  9/23/2020

  Novian Health Inc., a pioneer in destroying breast tumors with laser treatments, announced that it has been selected by as one of 50 companies in MedTech Innovator's flagship four-month Showcase and Accelerator program.

• FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma

  9/23/2020

  Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI® (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic

• New Non-Invasive Test for Lung Cancer Available Exclusively from LabCorp

  9/23/2020

  LabCorp, a leading global life sciences company that is focused on advancing health and guiding patient care decisions, has launched a new, non-invasive test for patients with non-small cell lung cancer.